Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025.Fourth positive DSMB ...

Reports collaboration and license revenue related to the Kyorin Agreement was $200K for the year ended 2024, which consisted of drug product ...

SAN DIEGO - aTyr Pharma, Inc. (NASDAQ: ATYR) reported a narrower-than-expected fourth quarter loss on Wednesday, but shares fell 4.8% in after-hours trading as investors focused on the company’s cash ...

The FDA approved a prefilled syringe format for Ani's purified Cortrophin Gel that should ease administration for MS patients ...

Staying passionate about it is easy. Her goal is to celebrate the rich heritage of Mexican cuisine — without compromising her ...